Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on Eli Lilly (NYSE: LLY) and raised the price target from $1410 to $1440. This adjustment reflects a positive outlook on the company's performance.